VANCOUVER, March 28, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted a U.S. patent that
covers the use of the Company's neuroprotective technology platform in the treatment of peripheral neuropathy. This includes the Company's lead drug candidate, davunetide, and pipeline product AL-309 as treatments for peripheral neuropathy caused by anti-cancer drugs.
Dr. Alistair Stewart, Allon's Vice President of Commercial Research,
said the Company's research has shown that its drug candidates are
active in preclinical models of peripheral neuropathy, including
neurotoxicity and neuropathic pain associated with anti-cancer therapy.
"These data lead us to conclude that AL-309 may have the potential to
prevent or reduce neurotoxicity when administered in combination with
anti-cancer agents known to cause peripheral neurotoxicity and
neuropathic pain," Stewart said.
Allon previously presented preclinical data at a Society for
Neurosciences meeting that showed the activity of AL-309 in
chemotherapy-induced neuropathy. AL-309, administered in combination with oxaliplatin (an anti-cancer agent)
reduced pain symptoms in a model of peripheral neuropathy.
The Society for Neurosciences, publisher of the Journal of Neuroscience,
is an organization of more than 40,000 basic scientists and clinicians
who study the brain and nervous system. The society is based in
"The granting of this US patent shows Allon's commitment to building
comprehensive intellectual property covering its technology in a
variety of settings, including disease prevention," Stewart said. This
new U.S. patent strengthens Allon's intellectual property estate which
includes 15 patent families, 62 issued patents and over 30 pending
About peripheral neuropathy
Peripheral neuropathy and neuropathic pain can result from a variety of
medical conditions, such as diabetes; or from the side-effects of drug
treatments, such as cancer chemotherapy. Peripheral neuropathy is
caused by damage to peripheral nerves that detect touch and painful
stimuli. Symptoms include tingling, hypersensitivity to light touch or
painful stimuli and chronic pain. These sensory problems can also
proceed to numbness and loss of sensitivity. Common qualities of the
painful neuropathy include burning or coldness, "pins and needles"
sensations, numbness and itching. Global drug sales for neuropathic
pain will reach an estimated $3 billion in 2012.
Allon Therapeutics Inc. is a clinical-stage biotechnology company
focused on bringing to market innovative central nervous system
therapies. Allon's lead drug davunetide is proceeding in a pivotal clinical trial in an orphan indication, in Progressive Supranuclear Palsy (PSP), under a Special Protocol Assessment (SPA) with the U.S. Food and
Drug Administration (FDA). The trial is fully enrolled and is expected
to complete patient dosing and release top-line data by late 2012. This
pivotal trial is based upon statistically significant human efficacy
demonstrated in patients with amnestic mild cognitive impairment (a
precursor to Alzheimer's disease), cognitive impairment associated with
schizophrenia, and in positive biomarker data.
The Company is listed on the Toronto Stock Exchange under the trading
Forward Looking Statements
Statements contained herein, other than those which are strictly
statements of historical fact may include forward-looking information.
Such statements will typically contain words such as "believes", "may",
"plans", "will", "estimate", "continue", "anticipates", "intends",
"expects", and similar expressions. While forward-looking statements
represent management's outlook based on assumptions that management
believes are reasonable, forward-looking statements by their nature are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or developments
expressed or implied by them. Such factors include, among others, the
inherent uncertainty involved in scientific research and drug
development, Allon's early stage of development, lack of product
revenues, its additional capital requirements, the risks associated
with successful completion of clinical trials and the long lead-times
and high costs associated with obtaining regulatory approval to market
any product which Allon may eventually develop. Other risk factors
include the limited protections afforded by intellectual property
rights, rapid technology and product obsolescence in a highly
competitive environment and Allon's dependence on collaborative
partners and contract research organizations. These factors can be
reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place
undue reliance on such forward-looking statements. Similarly, nothing
in this press release is meant to promote a pharmaceutical product or
make a regulated claim of efficacy.
Allon Therapeutics Inc.
Director, Investor Relations
SOURCE Allon Therapeutics Inc.